Toward Automated Insulin Delivery

This editorial discusses the advancements in automated insulin delivery systems for patients with type 1 diabetes, focusing on hybrid closed loop systems like the Tandem Control-IQ. A 6 month multicenter trial demonstrated that the closed loop system increased the time patients spent within the target glucose range (70–180 mg/dL) from 61% to 71%, with improved glycemic control and minimal hypoglycemia risk. Despite these benefits, challenges remain, including slow insulin absorption, sensor accuracy, and cost effectiveness. The study highlights the potential of closed loop systems to enhance diabetes management while acknowledging barriers to widespread adoption.

This editorial discusses the advancements in automated insulin delivery systems for patients with type 1 diabetes, focusing on hybrid closed loop systems like the Tandem Control-IQ. A 6 month multicenter trial demonstrated that the closed loop system increased the time patients spent within the target glucose range (70–180 mg/dL) from 61% to 71%, with improved glycemic control and minimal hypoglycemia risk. Despite these benefits, challenges remain, including slow insulin absorption, sensor accuracy, and cost effectiveness. The study highlights the potential of closed loop systems to enhance diabetes management while acknowledging barriers to widespread adoption.